文献速递头颈外科

头颈癌患者免疫检查点抑制剂治疗后的心血管事件作为肿瘤急症:610例分析

Cardiovascular events after cancer immunotherapy as oncologic emergencies: Analyses of 610 head and neck cancer patients treated with immune checkpoint inhibitors.
PubMed 文献 · Head Neck · 2023-12-27

回顾分析2016年4月1日至2020年12月31日期间在大规模三级癌症中心接受免疫检查点抑制剂(ICI)治疗的610例头颈癌(HNC)患者,中位随访12.3个月。无既往心血管病(CVD)的453例中,31.5%在ICI启动后至少出现1次CVD相关诊断,以快速性心律失常(91例新发事件)最常见;心肌炎诊断时间最早(中位2.5个月),心肌炎和快速性心律失常患者主要到急诊科就诊。

要点

  • 无既往CVD的HNC患者ICI后CVD相关诊断发生率为31.5%(143/453)。
  • 快速性心律失常是最常见的新发CVD诊断,共91例新发事件。
  • 心肌炎诊断时间最早,中位2.5个月,快速性心律失常中位4.9个月。

核心结论

  • ICI在HNC中的应用仍在扩大,ICI所致心血管毒性的迟发表现谱在HNC生存者中尚未完全明确。

研究设计与样本

  • 回顾性分析2016年4月1日至2020年12月31日期间在一家大型三级癌症中心接受ICI治疗的610例HNC患者。
  • 查阅病历获取人口学、临床和肿瘤相关数据,并通过计费数据库使用ICD-10编码查询CVD相关诊断。
  • 将急诊科就诊作为结局变量之一进行记录。
  • 中位随访时间为12.3个月(中位,四分位距=5-30个月)。

主要发现

  • 610例患者中,25.7%在ICI治疗前已有CVD。
  • 其余453例无既往CVD的患者中,31.5%(n=143)在ICI启动后至少出现1次CVD相关诊断。
  • ICI后最常见的CVD相关诊断为快速性心律失常(91例新发事件)。
  • 从ICI启动至诊断的时间:心肌炎最早(中位2.5个月,1.5-6.8个月),其次为心肌梗死(3.7个月,0.5-9个月)、心肌病(4.5个月,1.6-7.3个月)和快速性心律失常(4.9个月,1.2-11.4个月)。
  • 心肌炎和快速性心律失常患者主要到急诊科就诊。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardio-oncology and emergency medicine are closely collaborative, as many cardiac events in cancer patients require evaluation and treatment in the emergency department (ED). Immune checkpoint inhibitors (ICIs) have become a common treatment for patients with head and neck cancer (HNC). However, the immune-related adverse events (irAEs) from ICIs can be clinically significant. METHODS: We reviewed and analyzed cardiovascular diagnoses among HNC patients who received ICI during the period April 1, 2016-December 31, 2020 in a large tertiary cancer center. Demographics, clinical and cancer-related data were abstracted, and billing databases were queried for cardiovascular disease (CVD)-related diagnosis using International Classification of Disease-version10 (ICD-10) codes. We recorded receipt of care at the ED as one of the outcome variables. RESULTS: A total of 610 HNC patients with a median follow-up time of 12.3 months (median, interquartile range = 5-30 months) comprised our study cohort. Overall, 25.7% of patients had pre-existing CVD prior to ICI treatment. Of the remaining 453 patients without pre-existing CVD, 31.5% (n = 143) had at least one CVD-related diagnosis after ICI initiation. Tachyarrhythmias (91 new events) was the most frequent CVD-related diagnosis after ICI. The time to diagnosis of myocarditis from initiation of ICI occurred the earliest (median 2.5 months, 1.5-6.8 months), followed by myocardial infarction (3.7, 0.5-9), cardiomyopathy (4.5, 1.6-7.3), and tachyarrhythmias (4.9, 1.2-11.4). Patients with myocarditis and tachyarrhythmias mainly presented to the ED for care. CONCLUSION: The use of ICI in HNC is still expanding and the spectrum of delayed manifestation of ICI-induced cardiovascular toxicities is yet to be fully defined in HNC survivors.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Reyes-Gibby CC, Qdaisat A, Ferrarotto R, et al. Cardiovascular events after cancer immunotherapy as oncologic emergencies: Analyses of 610 head and neck cancer patients treated with immune checkpoint inhibitors. Head Neck. 2023. PMID: 38151809. doi:10.1002/hed.27604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。